What are the recommended medication options, dosing regimens, and duration for short‑term and second‑line management of insomnia in adults, including considerations for patients over 65 years and those with comorbid depression or anxiety?

Medication Management for Insomnia

First-Line Treatment

Cognitive behavioral therapy for insomnia (CBT-I) is the mandatory first-line treatment for chronic insomnia in all adults, including those over 65 and those with comorbid depression or anxiety. 1, 2 Pharmacotherapy should only be added when CBT-I alone is insufficient or unavailable. 1

Pharmacological Options When CBT-I Fails or as Adjunct

For Sleep Onset Insomnia

Recommended agents:

• Ramelteon 8 mg – preferred for sleep onset, particularly safe in elderly 1, 3
• Zaleplon 10 mg – short-acting option for sleep onset 1
• Zolpidem 10 mg (men) or 5 mg (women/elderly ≥65) – effective for sleep onset 1, 4
• Triazolam 0.25 mg – benzodiazepine option, use cautiously 1

For Sleep Maintenance Insomnia

Recommended agents:

• Suvorexant (orexin receptor antagonist) – can be used for 3+ months 1, 2
• Low-dose doxepin 3-6 mg – specifically for sleep maintenance 1, 3
• Daridorexant (dual orexin receptor antagonist) – newer option with 8-hour half-life, demonstrated 12-month efficacy 2, 5
• Lemborexant – another orexin antagonist option 5

For Both Sleep Onset and Maintenance

Recommended agents:

• Eszopiclone 2-3 mg – addresses both components 1
• Zolpidem extended-release 10 mg (men) or 5 mg (women/elderly) – dual action 3
• Temazepam 15 mg – benzodiazepine option, use cautiously 1

Critical Dosing Considerations for Patients ≥65 Years

All hypnotics require dose reduction in elderly patients due to increased fall risk (adjusted OR 1.72 for fractures) and cognitive impairment. 4

• Zolpidem: 5 mg maximum regardless of gender 4, 3
• Doxepin: ≤6 mg only (higher doses potentially inappropriate) 6
• Avoid benzodiazepines and non-benzodiazepine receptor agonists when possible – listed in Beers Criteria as potentially inappropriate 6
• Ramelteon 8 mg – no dose adjustment needed, safer profile 3
• Prolonged-release melatonin – can be used up to 3 months in patients ≥55 years 2

Duration of Treatment

Short-term use (≤4 weeks):

• Benzodiazepines 2
• Benzodiazepine receptor agonists (Z-drugs) 2
• Low-dose sedating antidepressants 2

Longer-term use (up to 3+ months):

• Orexin receptor antagonists (suvorexant, daridorexant, lemborexant) 2, 5
• Prolonged-release melatonin (≥55 years) 2

FDA approval limits most hypnotics to 4-5 weeks; longer use requires careful justification and ongoing monitoring. 4

Intermittent Dosing Strategy

For chronic insomnia requiring ongoing medication, prescribe intermittent (as-needed) dosing rather than nightly use. 4

• Prescribe 7 tablets per month (1-2 nights weekly) 4
• Instruct patients to take only on nights with significant sleep difficulty 4
• This strategy preserves efficacy while reducing adverse effects 4
• Particularly appropriate for zolpidem 10 mg 4

Medications NOT Recommended

Do not use the following agents (strong evidence against):

• Trazodone 50 mg – despite common off-label use, carries significant risks without proven benefit 1, 3
• Diphenhydramine – anticholinergic burden, particularly harmful in elderly 1
• Melatonin (immediate-release) – insufficient evidence for efficacy 1
• Tiagabine – not effective, should not be used 1, 3
• L-tryptophan – insufficient evidence 1
• Valerian – equivocal benefits 1, 3
• Antipsychotics – not recommended for insomnia 2

Special Populations

Comorbid Depression or Anxiety

Treat insomnia as a distinct disorder even when depression or anxiety is present. 5

• TD-CBT improves long-term quality of life primarily through sustained reduction in depressive symptoms 7
• Low-dose doxepin (3-6 mg) addresses both insomnia and may help depressive symptoms 1
• Orexin antagonists have no abuse potential and are safe with psychiatric comorbidities 5
• Do not rely on antidepressants prescribed for depression to treat insomnia – address insomnia directly 5

Contraindications

Absolute contraindications:

• Severe hepatic impairment (avoid zolpidem) 4
• Pregnancy (avoid zolpidem) 4
• Prior complex sleep behaviors (avoid zolpidem) 4
• Compromised respiratory function or sleep apnea (avoid all sedative-hypnotics) 4

Critical Safety Warnings

All patients must be counseled about:

• Complex sleep-related behaviors (sleep-driving, sleep-eating) – particularly with zolpidem 4
• Next-morning impairment – avoid driving or hazardous activities until fully awake 4
• Avoid alcohol and CNS depressants during treatment 4
• Take on empty stomach shortly before bedtime with ≥7-8 hours planned sleep 4
• Fall risk in elderly – particularly significant with benzodiazepines and Z-drugs 4

Monitoring and Follow-Up

Reassess efficacy and adverse effects every few weeks after initiation. 4

• If insomnia persists beyond 7-10 days of treatment, evaluate for underlying sleep disorders (polysomnography if treatment-resistant) 1, 4
• Consider actigraphy for differential diagnosis, not routine evaluation 2
• Regularly discuss benefits, harms, and costs with patients using shared decision-making 1, 4
• Monitor for withdrawal, rebound insomnia, and abuse potential (minimal with orexin antagonists) 5

Practical Implementation Algorithm

1. Initiate CBT-I (in-person, digital, or self-help book format) 1, 2, 8
2. If CBT-I insufficient after 4-6 weeks, add pharmacotherapy based on symptom pattern:
   • Sleep onset only → ramelteon 8 mg or zaleplon 10 mg
   • Sleep maintenance only → low-dose doxepin 3-6 mg or suvorexant
   • Both → eszopiclone 2-3 mg or daridorexant
3. Adjust dose for elderly (≥65): reduce all doses, prefer ramelteon or low-dose doxepin
4. Prescribe intermittently (7 tablets/month) rather than nightly 4
5. Limit initial trial to 4 weeks, then reassess
6. If effective and needed long-term, switch to orexin antagonist for sustained use 2, 5